Q3 FY2026 · ended Sep 30, 2026 · Revenue $874.50M, +8.7% YoY · Filed Oct 29, 2026
West Pharmaceutical Services, Inc. (WST) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $874.5 million and net income of $214.0 million. Free cash flow was $150.4 million. As of Sep 30, 2026 it held $464.1 million in cash and investments and $313.9 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- WST (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- PA
- Headquarters
- Exton, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 105770
- Former names
- WEST CO INC (until Feb 11, 1999)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $874.5M | $872.3M | $844.9M | $805.0M | $804.6M |
| Operating income | $267.4M | $179.1M | $177.1M | $156.6M | $167.6M |
| Net income | $214.0M | $154.0M | $138.8M | $132.1M | $140.0M |
| Diluted EPS | $3.02 | $2.15 | $1.92 | $1.82 | $1.92 |
| Operating cash flow | $189.5M | $124.0M | $89.9M | $251.1M | $197.2M |
| Free cash flow | $150.4M | $80.8M | $47.2M | $175.0M | $133.9M |
| Total assets | $4.1B | $4.1B | $4.1B | $4.3B | $4.1B |
| Total liabilities | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Stockholders' equity | $3.0B | $3.0B | $3.0B | $3.2B | $3.1B |
| Cash and investments | $464.1M | $435.8M | $521.4M | $791.3M | $628.5M |
| Total debt | $313.9M | $316.5M | $321.0M | $326.2M | $303.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Oct 26, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2026 | Jul 14, 2026 |
All 1000 West Pharmaceutical Services, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.